Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up in Resected, EGFR-mutated NSCLC By Ogkologos - April 2, 2025 747 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an exploratory analysis of the ADAURA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Mothers Raise Girls Together After Discovering They Were Swapped At Birth September 25, 2021 Kelly Preston, Actress And Wife Of John Travolta, Dies From Breast... July 13, 2020 Occurrence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan in Patients... May 8, 2021 Happy Nurses Month! May 3, 2021 Load more HOT NEWS Air Force Academy Cadet Donates 19-Inch Afro and Fundraises $39,000 for... Coronavirus reports – Part 9: “I am very relieved but I... Ribociclib Approval Expanded for Some Women with Advanced Breast Cancer HRQoL Data Support the Benefit of Adding Pembrolizumab to Chemotherapy in...
